Related Experiment Videos
Guidelines for immunizations in patients with inflammatory bowel disease
Bruce E Sands1, Carmen Cuffari, Jeffry Katz
1Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Inflammatory Bowel Diseases
|October 9, 2004
Summary
For patients with inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), most immunizations are safe and recommended. Efficacy may be reduced with immune suppression, but benefits often outweigh risks.
Area of Science:
- Immunology
- Gastroenterology
- Vaccinology
Background:
- Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), involves complex immune dysregulation.
- Therapeutic advancements in IBD have increasingly utilized immunosuppressive agents.
- Understanding the impact of IBD and its treatments on vaccine-preventable disease risk is crucial.
Framework:
- This review synthesizes current knowledge on immunization safety and efficacy in IBD patients.
- Recommendations are extrapolated from data on similar immune-mediated diseases and basic immunological principles.
- The interplay between IBD, immunosuppression, and vaccine response is examined.
Implementation:
- Routine immunization schedules for the general population are largely applicable to IBD patients.
- Live vaccines require careful consideration in immunocompromised individuals.
- Non-live vaccines are generally considered safe for IBD patients, even those on immunosuppressants.
Implications:
- Immunocompromised IBD patients may experience diminished vaccine efficacy.
- The benefits of preventing serious infections in at-risk IBD populations are significant.
- Current evidence suggests IBD-specific immunization guidelines are not generally required, aligning with general population recommendations.